[HTML][HTML] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

F Cantini, L Niccoli, D Matarrese, E Nicastri… - The Journal of …, 2020 - ncbi.nlm.nih.gov
F Cantini, L Niccoli, D Matarrese, E Nicastri, P Stobbione, D Goletti
The Journal of infection, 2020ncbi.nlm.nih.gov
As discussed in the Journal recently1 the SARS-CoV-2, a new β-Coronavirus, uses the
Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is
mediated by several factors, including clathrin, the adaptor protein-2 complex (AP2) and the
adaptor-associated kinase-1 (AAK1). 2 According to a recent report, 3 COVID-19, the
disease caused by SARS-CoV-2, is characterized by three clinical patterns: no symptoms,
mild to moderate disease, severe pneumonia requiring admission to Intensive Care Unit …
As discussed in the Journal recently1 the SARS-CoV-2, a new β-Coronavirus, uses the Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is mediated by several factors, including clathrin, the adaptor protein-2 complex (AP2) and the adaptor-associated kinase-1 (AAK1). 2 According to a recent report, 3 COVID-19, the disease caused by SARS-CoV-2, is characterized by three clinical patterns: no symptoms, mild to moderate disease, severe pneumonia requiring admission to Intensive Care Unit (ICU) in up to 31% of the patients. 3 Thus far, there is no specific therapy for COVID-19 infection. No benefit of lopinavir-ritonavir treatment resulted in a recent trial. 4 Hydroxychloroquine, currently used in view of its “in vitro” observed effect of reduction of viral replication, seems unsatisfactory. 5
ncbi.nlm.nih.gov